CIMMYT's eastern Africa product profile 2 (EA-PP2) focuses on developing high-yielding, late-maturing maize varieties with white grain, drought tolerance, NUE, and resistance to GLS, TLB, MSV, ear rots, and common rust, that are suitable for food use in tropical, rainfed, wet upper mid-altitude areas in eastern Africa and similar agroecologies. |
|
General Information |
|
Adaptation/Agroecological zone |
1300 - 2000 masl |
|
Type of product |
Three-way cross hybrid |
|
Year first announced |
2018 |
|
|
|
|
Grain Characteristics |
|
Grain color |
White |
|
Grain texture |
Semi-flint |
|
|
|
|
|
Grain Yield |
|
Biotic Stress Performance |
Grain yield under optimum conditions |
6.2 t/ha |
|
Turcicum leaf blight (TLB) (1-9) |
2.0 |
Grain yield under HD |
4.6 t/ha |
|
Grey leaf spot (GLS) (1-9) |
2.0 |
Grain yield under drought stress |
0.4 t/ha |
|
Common rust (1-9) |
2.6 |
Grain yield under low N stress |
2.8 t/ha |
|
Maize Lethal Necrosis (MLN) under art. inoc. (1-9) |
6.0 |
|
|
|
Grain weight loss (MW) |
19.6% |
Agronomic Characteristics |
|
Grain weight loss (LGB) |
14.5% |
Maturity |
77.1 DAP |
|
Ear Rots |
10.8% |
Plant height |
232 cm |
|
Diseases were originally scored on a 1-5 scale but have been converted here to a 1-9 scale, where 1 = Highly resistant; 5 = Tolerant; 9 = Highly susceptible. |
Ear height |
112 cm |
|
Bad husk cover |
5.7% |
|
|
|
Root lodging |
4.2% |
|
Comments |
Stalk lodging |
12.8% |
|
Product information is based on data from various trials conducted by CIMMYT in eastern Africa in 2017.
Abbreviations:
art. inoc. = artificial inoculation
DAP = days after planting
GLS = Grey Leaf Spot
HD = High Density (80,000 plants per ha)
Low N = managed low nitrogen
masl = meters above sea level
MD = managed drought
MSV = maize streak virus
NUE = Nitrogen Use Efficient
Opt = Optimum Management
TLB = Turcicum Leaf Blight |
Anthesis-silking interval |
1.6 Days |
|
Ear aspect (1-5) |
2.5 |
|
Plant aspect (1-5) |
2.6 |
|
Plant and ear aspects are scored on 1-5 scale, where 1 = desirable and 5 = undesirable characteristics |
|
|
|
|
|
Further Links |
|
Full Announcement |
|
Trial Data Summary |
|
Regional Trial Site Information |
|